[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
Identifieur interne : 000046 ( PubMed/Corpus ); précédent : 000045; suivant : 000047[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
Auteurs : H. Ben Salah ; M. Bahri ; H. Turki ; M. Abdelmoula ; M. Frikha ; J. DaoudSource :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1769-6658 ] ; 2011.
English descriptors
- KwdEn :
- Adolescent, Adult, Age of Onset, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bleomycin (administration & dosage), Brachytherapy (adverse effects), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (genetics), Carcinoma, Squamous Cell (radiotherapy), Carcinoma, Squamous Cell (surgery), Child, Cobalt Radioisotopes (adverse effects), Cobalt Radioisotopes (therapeutic use), Combined Modality Therapy, Female, Fluorouracil (administration & dosage), Humans, Male, Neoplasms, Multiple Primary (genetics), Neoplasms, Multiple Primary (radiotherapy), Neoplasms, Multiple Primary (surgery), Radiodermatitis (etiology), Radioisotope Teletherapy (adverse effects), Radiotherapy Dosage, Remission Induction, Retrospective Studies, Skin Neoplasms (drug therapy), Skin Neoplasms (genetics), Skin Neoplasms (radiotherapy), Skin Neoplasms (surgery), Tunisia (epidemiology), Xeroderma Pigmentosum (complications), Young Adult.
- MESH :
- chemical , administration & dosage : Bleomycin, Fluorouracil.
- geographic , epidemiology : Tunisia.
- adverse effects : Brachytherapy, Cobalt Radioisotopes, Radioisotope Teletherapy.
- complications : Xeroderma Pigmentosum.
- drug therapy : Carcinoma, Squamous Cell, Skin Neoplasms.
- etiology : Radiodermatitis.
- genetics : Carcinoma, Squamous Cell, Neoplasms, Multiple Primary, Skin Neoplasms.
- radiotherapy : Carcinoma, Squamous Cell, Neoplasms, Multiple Primary, Skin Neoplasms.
- surgery : Carcinoma, Squamous Cell, Neoplasms, Multiple Primary, Skin Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Cobalt Radioisotopes.
- Adolescent, Adult, Age of Onset, Child, Combined Modality Therapy, Female, Humans, Male, Radiotherapy Dosage, Remission Induction, Retrospective Studies, Young Adult.
Abstract
To analyze the therapeutic results of cutaneous cancers on xeroderma pigmentosum through a series of 15 patients treated by radiotherapy.
DOI: 10.1016/j.canrad.2011.02.007
PubMed: 21664850
Links to Exploration step
pubmed:21664850Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].</title><author><name sortKey="Ben Salah, H" sort="Ben Salah, H" uniqKey="Ben Salah H" first="H" last="Ben Salah">H. Ben Salah</name><affiliation><nlm:affiliation>Service de radiothérapie, CHU Habib-Bourguiba, route Majida-Bouleïla, Sfax, Tunisia. ben_salah_hanen@yahoo.fr</nlm:affiliation></affiliation></author><author><name sortKey="Bahri, M" sort="Bahri, M" uniqKey="Bahri M" first="M" last="Bahri">M. Bahri</name></author><author><name sortKey="Turki, H" sort="Turki, H" uniqKey="Turki H" first="H" last="Turki">H. Turki</name></author><author><name sortKey="Abdelmoula, M" sort="Abdelmoula, M" uniqKey="Abdelmoula M" first="M" last="Abdelmoula">M. Abdelmoula</name></author><author><name sortKey="Frikha, M" sort="Frikha, M" uniqKey="Frikha M" first="M" last="Frikha">M. Frikha</name></author><author><name sortKey="Daoud, J" sort="Daoud, J" uniqKey="Daoud J" first="J" last="Daoud">J. Daoud</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21664850</idno><idno type="pmid">21664850</idno><idno type="doi">10.1016/j.canrad.2011.02.007</idno><idno type="wicri:Area/PubMed/Corpus">000046</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000046</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].</title><author><name sortKey="Ben Salah, H" sort="Ben Salah, H" uniqKey="Ben Salah H" first="H" last="Ben Salah">H. Ben Salah</name><affiliation><nlm:affiliation>Service de radiothérapie, CHU Habib-Bourguiba, route Majida-Bouleïla, Sfax, Tunisia. ben_salah_hanen@yahoo.fr</nlm:affiliation></affiliation></author><author><name sortKey="Bahri, M" sort="Bahri, M" uniqKey="Bahri M" first="M" last="Bahri">M. Bahri</name></author><author><name sortKey="Turki, H" sort="Turki, H" uniqKey="Turki H" first="H" last="Turki">H. Turki</name></author><author><name sortKey="Abdelmoula, M" sort="Abdelmoula, M" uniqKey="Abdelmoula M" first="M" last="Abdelmoula">M. Abdelmoula</name></author><author><name sortKey="Frikha, M" sort="Frikha, M" uniqKey="Frikha M" first="M" last="Frikha">M. Frikha</name></author><author><name sortKey="Daoud, J" sort="Daoud, J" uniqKey="Daoud J" first="J" last="Daoud">J. Daoud</name></author></analytic><series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title><idno type="eISSN">1769-6658</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age of Onset</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bleomycin (administration & dosage)</term><term>Brachytherapy (adverse effects)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Carcinoma, Squamous Cell (genetics)</term><term>Carcinoma, Squamous Cell (radiotherapy)</term><term>Carcinoma, Squamous Cell (surgery)</term><term>Child</term><term>Cobalt Radioisotopes (adverse effects)</term><term>Cobalt Radioisotopes (therapeutic use)</term><term>Combined Modality Therapy</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Humans</term><term>Male</term><term>Neoplasms, Multiple Primary (genetics)</term><term>Neoplasms, Multiple Primary (radiotherapy)</term><term>Neoplasms, Multiple Primary (surgery)</term><term>Radiodermatitis (etiology)</term><term>Radioisotope Teletherapy (adverse effects)</term><term>Radiotherapy Dosage</term><term>Remission Induction</term><term>Retrospective Studies</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (genetics)</term><term>Skin Neoplasms (radiotherapy)</term><term>Skin Neoplasms (surgery)</term><term>Tunisia (epidemiology)</term><term>Xeroderma Pigmentosum (complications)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bleomycin</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Tunisia</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Brachytherapy</term><term>Cobalt Radioisotopes</term><term>Radioisotope Teletherapy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Xeroderma Pigmentosum</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Radiodermatitis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Neoplasms, Multiple Primary</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Neoplasms, Multiple Primary</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Neoplasms, Multiple Primary</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Cobalt Radioisotopes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age of Onset</term><term>Child</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Male</term><term>Radiotherapy Dosage</term><term>Remission Induction</term><term>Retrospective Studies</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To analyze the therapeutic results of cutaneous cancers on xeroderma pigmentosum through a series of 15 patients treated by radiotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21664850</PMID><DateCreated><Year>2011</Year><Month>8</Month><Day>12</Day></DateCreated><DateCompleted><Year>2011</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6658</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].</ArticleTitle><Pagination><MedlinePgn>400-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2011.02.007</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To analyze the therapeutic results of cutaneous cancers on xeroderma pigmentosum through a series of 15 patients treated by radiotherapy.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between 1993 and 2006, 15 patients with xeroderma pigmentosum and having cutaneous cancers were treated in the Radiotherapy Department of university hospital Habib-Bourguiba of Sfax in Tunisia. Seventy-three percent of the cases occurred in male patients and the mean age of appearance of the first tumour was 18.2 years. Tumour histology was squamous cell carcinoma in 74% of the cases. The total number of cutaneous tumours was 84. Ten patients had a surgical resection. Four patients did not respond to chemotherapy. The modality of irradiation was decided according to the size, thickness and localization of the tumour. The dose of radiotherapy was 60Gy or equivalent with classic irradiation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total number of lesions treated with radiotherapy was 64. Forty-three lesions were treated with contact therapy, ten with brachytherapy and 11 with cobalt therapy. The following acute complications were observed: cutaneous infection (53.3% of patients), radioepithelite (80% of patients) and necroses (33.3% of patients). Evaluation after treatment showed a clinical complete remission in 73% of the cases. Late effects were noted in seven cases: telangiectasy and cutaneous atrophy. A recurrence in the irradiated zone was observed in one case. A nodal metastasis was observed in two cases. Another patient presented lung metastases. After a median follow up of 37.2 months, four patients died, seven are alive with cutaneous cancer and four are alive with complete remission.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Radiotherapy is a possible and effective therapeutic alternative. Dose and methods are not defined for xeroderma pigmentosum.</AbstractText><CopyrightInformation>Copyright © 2011 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ben Salah</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Service de radiothérapie, CHU Habib-Bourguiba, route Majida-Bouleïla, Sfax, Tunisia. ben_salah_hanen@yahoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahri</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Turki</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Abdelmoula</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Frikha</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Daoud</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>FRE</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Radiothérapie des cancers cutanés au cours du xeroderma pigmentosum.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>Jun</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003037">Cobalt Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>11056-06-7</RegistryNumber><NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001761" MajorTopicYN="N">Bleomycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001918" MajorTopicYN="N">Brachytherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003037" MajorTopicYN="N">Cobalt Radioisotopes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009378" MajorTopicYN="N">Neoplasms, Multiple Primary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011855" MajorTopicYN="N">Radiodermatitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011867" MajorTopicYN="N">Radioisotope Teletherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011879" MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014416" MajorTopicYN="N" Type="Geographic">Tunisia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014983" MajorTopicYN="N">Xeroderma Pigmentosum</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21664850</ArticleId><ArticleId IdType="pii">S1278-3218(11)00088-6</ArticleId><ArticleId IdType="doi">10.1016/j.canrad.2011.02.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= CobaltMaghrebV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21664850
|texte= [Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21664850" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CobaltMaghrebV1
| This area was generated with Dilib version V0.6.32. |  |